Subsidiary JGL gets tax rectification relief, liability cut to Rs 42.41 cr

Regulatory & Legal View source PDF Explain this filing

JUBLPHARMA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-1.0%Reaction day

₹973.90

prior close

₹982.50

announcement price

After-mkt

timing

Nifty Smallcap 250market-0.4%-0.6% vs market

Pharmaceuticals peers, median of 163sector-0.6%-0.4% vs sector

On the reaction day the stock moved 0.6 pts less than Nifty Smallcap 250 and 0.4 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.9

10m

-0.8

15m

-0.9

30m

-1.0

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-1.0-0.4-0.6-0.6-0.4

Next day

-1.9-0.9-1.0-0.3-1.6

+0.2-0.4+0.5+0.4-0.2

+0.4+0.1+0.3+0.0+0.4

-0.2+1.1-1.3+0.2-0.4

-0.4+1.2-1.6+1.3-1.7

+0.8+0.9-0.2+0.1+0.7

15d

+4.9+1.2+3.7+0.8+4.1

-0.0+0.2-0.3+0.8-0.8

-8.1+3.2-11.3+1.4-9.5

+10.5+2.1+8.3+5.4+5.0

UpDownMarket · Nifty Smallcap 250Sector · Pharmaceuticals peers, median of 163Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Jubilant Generics Ltd (JGL), a wholly owned step-down subsidiary, received a Rectification Order from the Income Tax Department for AY 2023-24. Tax adjustments were reduced from Rs. 107.89 crs to Rs. 42.41 crs, a relief of about Rs. 65.48 crs in tax losses restored. The appeal on merit grounds is still being pursued before CIT(A) separately.

Likely market impact

Positive for Jubilant Pharmova as subsidiary tax liability drops by about 60 percent, easing near-term financials.